AMD

The flagship, light-based technology has received approval for applications in the anterior and posterior segments

The approval also grants Outlook Therapeutics an initial 10 years of market exclusivity in the EU for bevacizumab gamma (LYTENAVA)

The agency issued approval for Yesafili, from Biocon Biologics, and Opuviz, from Samsung Bioepis and Biogen

For decoding biomarkers, a multistage system is just the beginning

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March

Antonio Filipe Macedo, OD, MSc, PhD, speaks about his ARVO presentation on vision-related activity difficulties in patients with neovascular age-related macular degeneration

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

I-SCREEN will bring together 12 institutions across Europe, including Queen’s University Belfast

The European Commission is expected to make a decision about the application before the end of June

Research indicates smoking increases risk of AMD, cataracts and glaucoma

Physicians explore how other specialties adopt and integrate remote monitoring

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants

The trial will use vision preservation as a primary outcome measure, according to Annexon

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME

The study illustrates efficacy of AVT06 as compared with aflibercept (Eylea) for neovascular age-related macular degeneration

Real-world data from using faricimab to treat neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME)

The study results will help to identify dosing levels for future clinical trials

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD

The company received marketing authorisation approval in the EU earlier this year

The endorsement follows FDA approval in the United States this summer

Peter K. Kaiser, MD, provides an overview of innovative therapies in development for patients with dry age-related macular degeneration.

Arshad M. Khanani, MD, MA, FASRS, highlights the fluid resolution with faricimab and the need for loading doses, especially in high-needs switch patients with nAMD or DME.

Arshad M. Khanani, MD, MA, FASRS, discusses rapid improvement with faricimab in several anatomic parameters in treatment-naïve and previously treated patients with nAMD and DME in the TRUCKEE and TAHOE studies.

Data indicated switching to SB15 from AFL maintained comparable clinical efficacy and safety, confirming biosimilarity between these agents

Case 1 highlights the potential for this treatment for patients with dry AMD with noted letter gains